ScreenerHero

KLRS Kalaris Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · kalaristx.com
2.500USD-2.34%Mkt Cap: 59.51M $P/E: —

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular end…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap59.51M USD
Enterprise Value-28.82M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-43.44M USD
Revenue/Share—
Last Price2.500 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.60
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.10
EPS (TTM)-1.84
EPS (Forward)-1.66
52W Range
2.3502% of range11.88
52W High11.88 USD
52W Low2.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.11%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.37M USD
CapEx (TTM)200.00K USD
FCF Margin—
FCF Yield-44.09%
Net Debt-92.14M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio10.98
Quick Ratio10.71
Book Value/Sh2.42 USD
Cash/Share3.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:23
Split DateJan 16, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.71 USD
Upside (mean)+648.6%
Target Range7.000 USD – 25.00 USD
7.000+648.6% to mean25.00
# Analysts7
Ownership
Shares Out.23.80M
Float7.25M
Insiders8.81%
Institutions75.84%
Short Interest
Short Ratio5.5d
Short % Float3.82%
Short % Out.1.34%
Shares Short318.36K
Short (prev mo.)393.34K
Technical
SMA 503.620 (-30.9%)
SMA 2006.069 (-58.8%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)73.35K
Avg Vol (10d)70.51K
Technical Indicators
RSI (14)23.4
MACD-0.3070
MACD Signal-0.2816
MACD Hist.-0.0254
BB Upper3.574 USD
BB Middle3.009 USD
BB Lower2.444 USD
BB Width37.52%
ATR (14)0.2245 USD
Vol Ratio (20d)1.33x